

Online Supplementary Material

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in 3 Gulf countries. *JHEOR*. 2024;11(2):9-19. [doi:10.36469/jheor.2024.120288](https://doi.org/10.36469/jheor.2024.120288)


Figure S1: Results of One-way Sensitivity Analysis of Tawam, Emirates

Figure S2: Results of One-way Sensitivity Analysis of SSMC, Emirates

This supplementary material has been provided by the authors to give readers additional information about their work.




Figure S1. Results of One-way Sensitivity Analysis of Tawam, Emirates



The orange segment indicates the low value of the output, while the green segment indicates the high value of the output. Abbreviations: IV, intravenous; SC, subcutaneous.

Figure S2. Results of One-way Sensitivity Analysis of SSMC, Emirates



The light green segment indicates the low value of the output, while the dark green segment Abbreviations: D-KRd, daratumumab with carfilzomib, lenalidomide, and dexamethasone; D-Rd, daratumumab with lenalidomide and dexamethasone; D-Vd, daratumumab with bortezomib and dexamethasone; D-VRd, daratumumab with bortezomib, lenalidomide, and dexamethasone; NDMM, newly diagnosed multiple myeloma.